Estradiol/levonorgestrel continuous transdermal - Merck KGaA

Drug Profile

Estradiol/levonorgestrel continuous transdermal - Merck KGaA

Alternative Names: EMD 90171; Fem7 Plus; Fem7® Conti

Latest Information Update: 23 Jan 2013

Price : $50

At a glance

  • Originator Merck KGaA
  • Developer AbbVie
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Norpregnanes; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott Laboratories
  • 09 Apr 2009 No development reported - Phase-III for Menopausal syndrome in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top